Abstract
穆秋玥,冯添,黄飞,罗周,焦宇航,高源雪,管庆虎,陈虎,张锐智.3岁及以上人群新型冠状病毒灭活疫苗接种反应临床观察分析[J].Chinese journal of Epidemiology,2023,44(11):1738-1743
3岁及以上人群新型冠状病毒灭活疫苗接种反应临床观察分析
Clinical observation on adverse reaction after vaccination of inactivated 2019-nCoV vaccine in population aged 3 years and above
Received:March 28, 2023  
DOI:10.3760/cma.j.cn112338-20230328-00189
KeyWord: 新型冠状病毒灭活疫苗  安全性  不良反应
English Key Word: Inactivated 2019-nCoV vaccine  Safety  Adverse reaction
FundProject:
Author NameAffiliationE-mail
Mu Qiuyue Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Feng Tian Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Huang Fei Department for Immunization Planning, Yanhe County Center for Disease Control and Prevention of Guizhou, Yanhe 565300, China  
Luo Zhou Department for Immunization Planning, Yanhe County Center for Disease Control and Prevention of Guizhou, Yanhe 565300, China  
Jiao Yuhang Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Gao Yuanxue Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Guan Qinghu Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Chen Hu Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China  
Zhang Ruizhi Institute for Immunization Planning, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China 919987774@qq.com 
Hits: 2616
Download times: 631
Abstract:
      目的 评价贵州省≥3岁人群接种新型冠状病毒(新冠病毒)灭活疫苗的安全性。方法 采用开放式设计,于2021年6月至2022年7月在贵州省沿河县招募符合条件的人群,按照(0,28)d免疫程序接种2剂次新冠病毒灭活疫苗,收集每剂次疫苗接种后30 min内和0~28 d的不良反应,分年龄、剂次、患病情况分析不良反应发生率。结果 总不良反应发生率为1.51%(294/19 458),所有不良反应均发生在接种后7 d内,严重程度为1级或2级,以接种部位疼痛最常见。3~、18~和≥60岁组不良反应发生率分别为1.01%(58/5 721)、2.44%(220/9 017)和0.34%(16/4 720),差异有统计学意义(P<0.001)。第1剂次接种后不良反应发生率(1.20%,233/19 458)高于第2剂次(0.37%,61/16 368),差异有统计学意义(P<0.001)。≥60岁组中健康人群和患基础疾病人群不良反应发生率分别为0.36%(9/2 520)和0.32%(7/2 200),差异无统计学意义(P=0.818)。结论 ≥3岁人群接种新冠病毒灭活疫苗安全性良好,在老年健康人群和患基础疾病人群中接种均具有良好安全性。
English Abstract:
      Objective To evaluate the safety of mass vaccination of inactivated 2019-nCoV vaccine in population aged ≥ 3 years in Guizhou Province. Methods The open-label study was conducted in eligible volunteers in Yanhe County of Guizhou from June 2021 to July in 2022. In the study, two doses of the inactivated 2019-nCoV vaccine were given at (0, 28) days according to the immunization schedule. The information about adverse reaction (AR) within 30 minutes and during 0-28 days after vaccination were collected, and the incidence of AR was analyzed by age, doses, and health status. Results The overall incidence of AR was 1.51% (294/19 458), all ARs, mainly pain at injection site, occurred within 7 days after the vaccination, the AR grade was 1-2. The incidence of AR was 1.01% in age group 3- years (58/5 721), 2.44% in age group 18- years (220/9 017), and 0.34% in age group ≥ 60 years (16/4 720). The differences were significant (P<0.001). The incidence of AR after the first dose vaccination (1.20%, 233/19 458) was significantly higher than that after the second dose (0.37%, 61/16 368), the difference was significant (P<0.001). In the elderly aged ≥ 60 years, the incidence of AR was 0.36% (9/2 520) in healthy group and 0.32% (7/2 200) in group with underlying medical conditions, the differences were not significant (P=0.818). Conclusion The domestic inactivated 2019-nCoV vaccine showed good safety in mass vaccination in population aged ≥ 3 years, including the elderly in both healthy group and group with underlying medical conditions.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close